Celltrion partners with US pharmacy chain for Yuflyma sales
Celltrion Healthcare, Celltrion's distribution unit, said Monday it has signed a deal with US specialty pharmacy chain CarePartners Pharmacy to sell its Humira biosimilar Yuflyma in the US market.
CarePartners Pharmacy is a national pharmacy that distributes medications across all 50 states and Washington DC, focusing on several niche programs, including autoimmune therapies.
Under the contract, Yuflyma will be distributed to drug stores operated by CarePartners Pharmacy nationwide, starting from the end of this month.
Celltrion said the partnership is expected to raise the presence of the Yuflyma autoimmune disease biosimilar among over 10 million patients in the US.
Yuflyma will be the only adalimumab sold at CarePartners Pharmacy drugstores as the US partner has decided not to sell AbbVie's blockbuster drug Humira and other competing biosimilars in the market.
Celltrion said it could ink the exclusive contract due to the drug's convenience both for patients and health care providers.
“Yuflyma uses a high concentration, citrate-free formulation, causing less pain when injected. The medication also comes with a latex-free injectable device, which can reduce allergy risk,” an official from Celltrion said.
Meanwhile, Celltrion Healthcare said the company will tap pharmacy benefit managers (PBMs), including Optum, to enlist Yuflyma in their formulary lists.
PBMs are companies that manage prescription drug benefits on behalf of health insurers. They negotiate fees and rebates with drug providers and create formulary lists of medications covered by insurance and reimburse pharmacies for patients' prescriptions.
Celltrion Healthcare said the company will increase its marketing efforts, with a goal of capturing around 40 percent share in the PBM market for adalimumab by the end of this year.
(责任编辑:커뮤니티)
下一篇:S. Korea's Busan making last
- ·Dodgers prospect trying to fit in with S. Korean nat'l baseball team
- ·Allies vow stern measures against Russia
- ·[Herald Interview] ‘Another Body,’ a riveting documentary on devasting effects of deepfake porn
- ·[Weekender] Behind the scenes of Korean food crazes
- ·Surveillance cameras to be a must in hospital operating rooms
- ·[Herald Interview] Jung Soo
- ·Seoul shares close lower amid woes over Fed's drawn
- ·Mirae Asset continues to lead domestic equity ETF market
- ·Hanwha Ocean developing submarine stealth technology
- ·SK hynix starts supply of world’s fastest mobile DRAM for China's Vivo
- ·Seoul shares down amid possible US government shutdown woes
- ·Daewoong's Nabota tops botulinum toxin exports
- ·BOK likely to keep policy rate unchanged on slowdown, hope for Fed's rate freeze, easing inflation
- ·LG Twins crowned champions for 1st time since 1994 as S. Korean baseball season ends
- ·UNESCO HQ hit by largest
- ·Redbreast 15 Year Old whiskey debuts in Korea
- ·Music industry seeks solution to ticket scalping through public discussion
- ·Korea, Japan airport operators hold first post
- ·Criminal procedures for foreigners in Korea
- ·British interdisciplinary artist Jane Benson turns literary texts into art
- ·9·19 합의 취약점 '대북 감시' 공백, 미국 위성으로 메운다
- ·Dunamu hosts forum on blockchain's potential
- ·Seoul shares close more than 1% higher on extended Israel
- ·JYP to 'take K
- ·Music director, composer Jung Jae
- ·[From the Scene] Building 100
- ·[Herald Interview] 'Korea strives to set global standards for data protection in generative AI era'
- ·LG Twins crowned champions for 1st time since 1994 as S. Korean baseball season ends